Actionable news
All posts from Actionable news
Actionable news in BMY: BRISTOL-MYERS SQUIBB CO.,

FDA accepts for review Bristol-Myers' sBLA for Opdivo in advanced kidney cancer

The FDA accepts for review the supplemental Biologics License Application (sBLA) from Bristol-Myers Squibb (NYSE:BMY) seeking clearance for the use of Opdivo (nivolumab) in patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. The PDUFA date for the...